Anna Gladfelter
Pulmonary Disease · Hattiesburg, MSNPI 1750843330
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 137 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,139, more than ten times the $13 reported in 2020. That places this record below the midpoint for pulmonary disease clinicians in MS, where the typical reported total is $4,861.
Across 137 payments — averaging $21.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$387
- Pfizer$353
- AbbVie$303
- Mallinckrodt Hospital Products Inc.$287
- AstraZeneca$251
- Regeneron Healthcare Solutions, Inc.$201
- plus $1K from 17 others
What the payments were for
- Food & beverage$2,914100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 21 | $387 |
| Pfizer | 18 | $353 |
| AbbVie | 16 | $303 |
| Mallinckrodt Hospital Products Inc. | 12 | $287 |
| AstraZeneca | 8 | $251 |
| Regeneron Healthcare Solutions, Inc. | 8 | $201 |
| GSK | 9 | $165 |
| Merck | 8 | $147 |
| United Therapeutics Corporation | 3 | $96 |
| Sanofi | 4 | $94 |
| Inari Medical, Inc. | 4 | $93 |
| Viatris Specialty LLC | 4 | $82 |
| Verona Pharma, Inc. | 3 | $63 |
| ANI Pharmaceuticals, Inc. | 3 | $58 |
| Grifols USA, LLC | 2 | $52 |
| Novo Nordisk | 3 | $52 |
| La Jolla Pharmaceutical Company | 2 | $47 |
| Actelion Pharmaceuticals US, Inc. | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Ambu Inc. | 1 | $33 |
| Insmed, Inc. | 2 | $31 |
| Shionogi Inc | 1 | $21 |
| Bayer | 1 | $17 |
How this compares
$2,914 in reported general payments places this provider in the 35th percentile of 101 pulmonary disease providers in Mississippi.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $263 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Hattiesburg
- L AldredHattiesburg$76K
- Walid YounisHattiesburg$15K
- Tamer HudaliHattiesburg$15K
- Michael RaggioHattiesburg$11K
- Lewis NeeseHattiesburg$9K
- Kevin KinlochHattiesburg$6K
- Randolph RossHattiesburg$5K
- Charles McCollumHattiesburg$4K
- Andrew RognessHattiesburg$4K
- William FrazierCanton$809K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.